Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros

Base de dados
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Curr Treat Options Oncol ; 22(10): 95, 2021 09 13.
Artigo em Inglês | MEDLINE | ID: mdl-34515857

RESUMO

OPINION STATEMENT: While emergency use is authorized for numerous COVID-19 vaccines and the high-risk population including cancer patients or those with immunosuppression due to disease or therapy is prioritized, data on this group's specific safety and efficacy of these vaccines remains limited. Safety data from clinical trials and population data may be extrapolated, and these vaccines may be used for cancer patients. However, concerns of efficacy due to the variable immune response in patients with active cancers undergoing active therapy and cancer survivors with chronic immunosuppression remain. The authors aim to discuss the current recommendations for use of COVID-19 vaccination in patients with cancer.


Assuntos
Vacinas contra COVID-19/efeitos adversos , Vacinas contra COVID-19/uso terapêutico , COVID-19/prevenção & controle , Neoplasias/imunologia , Vacinação/efeitos adversos , COVID-19/complicações , Humanos , Sistema Imunitário , Imunização , Hospedeiro Imunocomprometido , Terapia de Imunossupressão , Oncologia/normas , Neoplasias/complicações , Segurança do Paciente , Guias de Prática Clínica como Assunto , SARS-CoV-2 , Resultado do Tratamento
2.
Eur J Surg Oncol ; 50(6): 108343, 2024 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-38640606

RESUMO

BACKGROUND: Advances in perioperative chemotherapy have improved outcomes in patients with gastric cancers (GC). This strategy leads to tumour downstaging and may result in a pathologic complete response (pCR). The study aimed to evaluate the predictors of pCR and determine the impact of pCR on long-term survival. METHODS: At the Department of Gastrointestinal and HPB Oncology at the Tata Memorial Centre, Mumbai, 1001 consecutive patients with locally advanced GCs undergoing radical resection following neoadjuvant chemotherapy from January 2005 to June 2022 were included. RESULTS: At a median follow-up of 61 months, the median OS was 53 months with a 5-year OS of 46.8 %. Ninety-five patients (9.49 %) realized pCR. Non-signet and well-differentiated histology were associated with pCR. pCR was significantly associated with improved OS, 5-year OS 79.2 % vs 43.2 % (HR 0.30, p < 0.001). On multivariable analysis, the realization of pCR and completion of adjuvant chemotherapy had superior OS. Whereas, signet-ring histology, linitis-like tumours, and high lymph node ratio had adverse outcomes. CONCLUSION: Tumour grade and signet-ring histology predict achievement of pCR in locally advanced GCs after neoadjuvant chemotherapy. Patients with pCR have significantly improved survival. Future neoadjuvant strategies should focus on enhancing pCR rates to improve overall outcomes.


Assuntos
Excisão de Linfonodo , Terapia Neoadjuvante , Neoplasias Gástricas , Humanos , Neoplasias Gástricas/patologia , Neoplasias Gástricas/tratamento farmacológico , Neoplasias Gástricas/terapia , Masculino , Feminino , Pessoa de Meia-Idade , Idoso , Quimioterapia Adjuvante , Adulto , Gastrectomia , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Estadiamento de Neoplasias , Taxa de Sobrevida , Gradação de Tumores , Carcinoma de Células em Anel de Sinete/patologia , Carcinoma de Células em Anel de Sinete/tratamento farmacológico , Estudos Retrospectivos , Fluoruracila/uso terapêutico , Fluoruracila/administração & dosagem , Adenocarcinoma/tratamento farmacológico , Adenocarcinoma/patologia , Adenocarcinoma/terapia , Adenocarcinoma/genética
3.
SN Compr Clin Med ; 2(12): 2691-2701, 2020.
Artigo em Inglês | MEDLINE | ID: mdl-33251481

RESUMO

In the wake of the COVID-19 pandemic, due to reasons beyond control, health care workers have struggled to deliver treatment for the patients with cancer. The concern for otherwise healthy patients with curable cancers that require timely intervention or therapy is the risk of contracting COVID-19 may outweigh the benefits of cancer treatment. Lack of international guidelines leaves health care providers with a case-to-case approach for delivering optimal cancer care in the wake of the pandemic. Transition to telemedicine has somewhat bridged the gap for in-office visits, but there is a continuing challenge of delays in cancer screening or significant decline of new diagnoses of cancers due to the pandemic. We aim to propose a balance in risk from treatment delay versus risks from COVID-19 with emphasis on treatment modality (surgery, radiation, and systemic therapy) as well as supportive care for cancer patients, and therefore have reviewed the publications and recommendations from international societies and study groups available as of October 2020.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA